Strategies for preserving residual renal function in peritoneal dialysis patients

Clinical Kidney Journal

Volumn 8, Issue 2, 2015, Pages 202-211

  Nongnuch, Arkom ^a,b   Assanatham, Montira ^a   Panorchan, Kwanpeemai ^b,c   Davenport, Andrew ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c BUMRUNGRAD INTERNATIONAL HOSPITAL   (Thailand)

Author keywords

Biocompatible dialysate ACEI; Peritoneal dialysis; Residual renal function

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ICODEXTRIN; LOOP DIURETIC AGENT; RENIN;

ARTICLE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; HUMAN; KIDNEY FUNCTION; MEASUREMENT; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NEPHROTOXICITY; PERITONEAL DIALYSIS; PERITONEAL FLUID; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESIDUAL RENAL FUNCTION; SYSTEMATIC REVIEW (TOPIC); URINE VOLUME;

EID: 84942105095     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sfu140     Document Type: Article

References (106)

1. Chung SH, Heimbürger O, Lindholm B et al. Peritoneal dialysis patient survival: A comparison between a Swedish and a Korean centre. Nephrol Dial Transplant 2005; 20: 1207-1213
2. Davenport A. Peritonitis remains the major clinical complication of peritoneal dialysis: The London, UK, peritonitis audit 2002-2003. Perit Dial Int 2009; 29: 297-302
3. Szeto CC, Wong TY, Chow KM et al. Independent effects of renal and peritoneal clearances on the mortality of peritoneal dialysis patients. Perit Dial Int 2004; 24: 58-64
4. Maiorca R, Brunori G, Zubani R et al. Predictive value of dialysis adequacy and nutritional indices for mortality and morbidity in CAPD and HD patients. A longitudinal study. Nephrol Dial Transplant 1995; 10: 2295-2305
5. Diaz-Buxo JA, Lowrie EG, Lew NL et al. Associates of mortality among peritoneal dialysis patients with special reference to peritoneal transport rates and solute clearance. Am J Kidney Dis 1999; 33: 523-534
6. Rocco M, Soucie JM, Pastan S et al. Peritoneal dialysis adequacy and risk of death. Kidney Int 2000; 58: 446-457
7. Shemin D, Bostom AG, Lambert C et al. Residual renal function in a large cohort of peritoneal dialysis patients: Change over time, impact on mortality and nutrition. Perit Dial Int 2000; 20: 439-444
8. Rocco MV, Frankenfield DL, Prowant B et al.; Centers for Medicare & Medicaid Services Peritoneal Dialysis Core Indicators Study Group. Risk factors for early mortality in U.S. peritoneal dialysis patients: Impact of residual renal function. Perit Dial Int 2002; 22: 371-379
9. Szeto CC, Wong TY, Chow KM et al. Independent effects of renal and peritoneal clearances on the mortality of peritoneal dialysis patients. Perit Dial Int 2004; 24: 58-64
10. Szeto CC,Wong TY, Leung CB et al. Importance of dialysis adequacy in mortality and morbidity of Chinese CAPD patients. Kidney Int 2000; 58: 400-407
11. Ates K, Nergizoglu G, Keven K et al. Effect of fluid and sodium removal on mortality in peritoneal dialysis patients. Kidney Int 2001; 60: 767-776
12. Bargman JM, Thorpe KE, Churchill DN et al. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: A reanalysis of the CANUSA study. J Am Soc Nephrol 2001; 12: 2158-2162
13. Paniagua R, Amato D, Vonesh E et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002; 13: 1307-1320
14. Termorshuizen F, Korevaar JC, Dekker FW et al. The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: An analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. Am J Kidney Dis 2003; 41: 1293-1302
15. Chung SH, Heimburger O, Stenvinkel P et al. Association between residual renal function, inflammation and patient survival in new peritoneal dialysis patients. Nephrol Dial Transplant 2003; 18: 590-597
16. Rumpsfeld M, McDonald SP, Johnson DW. Peritoneal small solute clearance is nonlinearly related to patient survival in the Australian and New Zealand peritoneal dialysis patient populations. Perit Dial Int 2009; 29: 637-646
17. Suda T, Hiroshige K, Ohta T et al. The contribution of residual renal function to overall nutritional status in chronic haemodialysis patients. Nephrol Dial Transplant 2000; 15: 396-401
18. Davenport A, Cholongitas E, Xirouchakis E et al. Pitfalls in assessing renal function in patients with cirrhosis-potential inequity for access to treatment of hepatorenal failure and liver transplantation. Nephrol Dial Transplant 2011; 26: 2735-2742
19. van Olden RW, Krediet RT, Struijk DG et al. Measurement of residual renal function in patients treated with continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 1996; 7: 745-750
20. Caravaca F, Arrobas M, Pizarro JL et al. Uraemic symptoms, nutritional status and renal function in pre-dialysis endstage renal failure patients. Nephrol Dial Transplant 2001; 16: 776-782
21. Peritoneal Dialysis Adequacy Work Group: NKF-K/DOQI Clinical Practice Guidelines for peritoneal dialysis adequacy: Update 2006. Am J Kidney Dis 2006; 48(Suppl 1): S98-S129
22. Fürstenberg A, Davenport A. Assessment of body composition in peritoneal dialysis patients using bioelectrical impedance and dual-energy x-ray absorptiometry. Am J Nephrol 2011; 33: 150-156
23. Davenport A. AKI in a patient with cirrhosis and ascites. Clin J Am Soc Nephrol 2012; 7: 2041-2048
24. Hoste EA, Cruz DN, Davenport A et al. The epidemiology of cardiac surgery-associated acute kidney injury. Int J Artif Organs 2008; 31: 158-165
25. Agarwal R. Reproducibility of renal function measurements in adult men with diabetic nephropathy: Research and clinical implications. Am J Nephrol 2007; 27: 92-100
26. Haynes R, Staplin N, Emberson J et al. Evaluating the contribution of the cause of kidney disease to prognosis in CKD: Results from the Study of Heart and Renal Protection (SHARP). Am J Kidney Dis 2014; 64: 40-48
27. Liao CT, Chen YM, Shiao CC et al. Rate of decline of residual renal function is associated with all-cause mortality and technique failure in patients on long-term peritoneal dialysis. Nephrol Dial Transplant 2009; 24: 2909-2914
28. Moist LM, Port FK, Orzol SM et al. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 2000; 11: 556-564
29. Davenport A. Intradialytic complications during hemodialysis. Hemodial Int 2006; 10: 162-167
30. Szeto CC, Kwan BC, Chow KM et al. Predictors of residual renal function decline in patients undergoing continuous ambulatory peritoneal dialysis. Perit Dial Int 2014; PMID: 24497594 [Epub ahead of print]
31. Palomo-Piñón S, Mora-Villalpando CJ, Del Carmen Prado- Uribe M et al. Inflammation and myocardial damage markers influence loss of residual renal function in peritoneal dialysis patients. Arch Med Res 2014 pii: S0188-4409(14) 00156-8
32. Klahr S, Levey AS, Beck GJ et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994; 330: 877-884
33. Levey AS, Greene T, Sarnak MJ et al. Effect of dietary protein restriction on the progression of kidney disease: Long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study. Am J Kidney Dis 2006; 48: 879-888
34. Menon V, Kopple JD, Wang X et al. Effect of a very lowprotein diet on outcomes: Long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study. Am J Kidney Dis 2009; 53: 208-217
35. Jiang N, Qian J, Sun Wet al. Better preservation of residual renal function in peritoneal dialysis patients treated with a low-protein diet supplemented with keto acids: A prospective, randomized trial.Nephrol Dial Transplant 2009; 24: 2551-2558
36. Johnson DW, Mudge DW, Sturtevant JM et al. Predictors of decline of residual renal function in new peritoneal dialysis patients. Perit Dial Int 2003; 23: 276-283
37. House AA, Anand I, Bellomo R et al.; Acute Dialysis Quality Initiative Consensus Group. Definition and classification of Cardio-Renal Syndromes: Workgroup statements from the 7th ADQI Consensus Conference. Nephrol Dial Transplant 2010; 25: 1416-1420
38. Marcantoni C, Jafar TH, Oldrizzi L et al. The role of systemic hypertension in the progression of nondiabetic renal disease. Kidney Int Suppl 2000; 75: S44-S48
39. Jansen MA, Hart AA, Korevaar JC et al. Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int 2002; 62: 1046-1053
40. Davenport A, Anker SD, Mebazaa A et al.; Acute Dialysis Quality Initiative (ADQI) consensus group. ADQI 7: The clinical management of the Cardio-Renal syndromes: Work group statements from the 7th ADQI consensus conference. Nephrol Dial Transplant 2010; 25: 2077-2089
41. Siew E, Davenport A. The growth of acute kidney injury. A rising tide of just attention to injury? Kidney Int 2014; doi: 10.1038/ki.2014.293
42. Kolesnyk I, Noordzij M, Dekker FW et al. Treatment with angiotensin II inhibitors and residual renal function in peritoneal dialysis patients. Perit Dial Int 2011; 31: 53-59
43. Li PK, Chow KM,Wong TY et al. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Ann Intern Med 2003; 139: 105-112
44. Suzuki H, Kanno Y, Sugahara S et al. Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. Am J Kidney Dis 2004; 43: 1056-1064
45. Reyes-Marin FA, Calzada C, Ballesteros A et al. Comparative study of enalapril vs. losartan on residual renal function preservation in automated peritoneal dialysis. A randomized controlled study. Res Invest Clin 2012; 64: 315-321
46. Zhang L, Zeng X, Fu P et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in peritoneal dialysis patients. Cochrane Database Syst Rev 2014; 6: CD009120
47. Phakdeekitcharoen B, Leelasa-nguan P. Effects of an ACE inhibitor or angiotensin receptor blocker on potassium in CAPD patients. Am J Kidney Dis 2004; 44: 738-746
48. van Olden RW, Guchelaar HJ, Struijk DG et al. Acute effects of high-dose furosemide on residual renal function in CAPD patients. Perit Dial Int 2003; 23: 339-347
49. Medcalf JF, Harris KP, Walls J. Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis. Kidney Int 2001; 59: 1128-1133
50. Selby NM, Fonseca S, Hulme L et al. Automated peritoneal dialysis has significant effects on systemic hemodynamics. Perit Dial Int 2006; 26: 328-335
51. Hiroshige K, Yuu K, Soujima M et al. Rapid decline of residual renal function in patients on automated peritoneal dialysis. Perit Dial Int 1996; 16: 307-315
52. Hufnagel G, Michel C, Queffeulou G et al. The influence of automated peritoneal dialysis on the decrease in residual renal function. Nephrol Dial Transplant 1999; 14: 1224-1228
53. de Fijter CW, ter Wee PM, Donker AJ. The influence of automated peritoneal dialysis on the decrease in residual renal function. Nephrol Dial Transplant 2000; 15: 1094-1096
54. Balasubramanian G, McKitty K, Fan SL. Comparing automated peritoneal dialysis with continuous ambulatory peritoneal dialysis: Survival and quality of life differences? Nephrol Dial Transplant 2011; 26: 1702-1708
55. Cnossen TT, Usvyat L, Kotanko P et al. Comparison of outcomes on continuous ambulatory peritoneal dialysis versus automated peritoneal dialysis: Results from a USA database. Perit Dial Int 2011; 31: 679-684
56. Rodriguez AM, Diaz NV, Cubillo LP et al. Automated peritoneal dialysis: A Spanish multicentre study. Nephrol Dial Transplant 1998; 13: 2335-2340
57. Bro S, Bjorner JB, Tofte-Jensen P et al. A prospective, randomized multicenter study comparing APD and CAPD treatment. Perit Dial Int 1999; 19: 526-533
58. Gallar P, Ortega O, Carreno A et al. Rate of decline in residual renal function is equal in CAPD and automated peritoneal dialysis patients. Perit Dial Int 2000; 20: 803-805
59. Singhal MK, Bhaskaran S, Vidgen E et al. Rate of decline of residual renal function in patients on continuous peritoneal dialysis and factors affecting it. Perit Dial Int 2000; 20: 429-438
60. Holley JL, Aslam N, Bernardini J et al. The influence of demographic factors and modality on loss of residual renal function in incident peritoneal dialysis patients. Perit Dial Int 2001; 21: 302-305
61. Hidaka H, Nakao T. Preservation of residual renal function and factors affecting its decline in patients on peritoneal dialysis. Nephrology 2003; 8: 184-191
62. Rodriguez-Carmona A, Perez-Fontan M, Garca-Naveiro R et al. Compared time profiles of ultrafiltration, sodium removal, and renal function in incident CAPD and automated peritoneal dialysis patients. Am J Kidney Dis 2004; 44: 132-145
63. Rabindranath KS, Adams J, Ali TZ et al. Automated vs continuous ambulatory peritoneal dialysis: A systematic review of randomized controlled trials. Nephrol Dial Transplant 2007; 22: 2991-2998
64. Su YJ, Lee CT, Chuang FR et al. Comparison of clinical characteristics between automated peritoneal dialysis and continuous ambulatory peritoneal dialysis: A 2-year singlecenter observational study. Ren Fail 2010; 32: 817-824
65. Michels WM, Verduijn M, Grootendorst DC et al. Decline in residual renal function in automated compared with continuous ambulatory peritoneal dialysis. Clin J Am Soc Nephrol 2011; 6: 537-542
66. Williams JD, Topley N, Craig KJ et al. The Euro-Balance Trial: The effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004; 66: 408-418
67. Feriani M, Kirchgessner J, La Greca G et al. Randomized longterm evaluation of bicarbonate-buffered CAPD solution. Kidney Int 1998; 54: 1731-1738
68. Coles GA, O'Donoghue DJ, Pritchard N et al. A controlled trial of two bicarbonate-containing dialysis fluids for CAPD-final report. Nephrol Dial Transplant 1998; 13: 3165-3171
69. Rippe B, Simonsen O, Heimburger O et al. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001; 59: 348-357
70. Szeto CC, Chow KM, Lam CWet al. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucosedegradation products-A 1-year randomized control trial. Nephrol Dial Transplant 2007; 22: 552-559
71. Fan SL, Pile T, Punzalan S et al. Randomized controlled study of biocompatible peritoneal dialysis solutions: Effect on residual renal function. Kidney Int 2008; 73: 200-206
72. Bajo MA, Perez-Lozano ML, Albar-Vizcaino P et al. Low-GDP peritoneal dialysis fluid ('balance') has less impact in vitro and ex vivo on epithelial-to-mesenchymal transition (EMT) of mesothelial cells than a standard fluid. Nephrol Dial Transplant 2011; 26: 282-291
73. Johnson DW, Brown FG, Clarke M et al. Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes. J Am Soc Nephrol 2012; 23: 1097-1107
74. Choi HY, Kim DK, Lee TH et al. The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: An open randomized prospective trial. Perit Dial Int 2008; 28: 174-182
75. Cho KH, Do JY, Park JWet al. The effect of low-GDP solution on ultrafiltration and solute transport in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 2013; 33: 382-390
76. Pajek J, Kveder R, Bren A et al. Short-term effects of bicarbonate/ lactate-buffered and conventional lactate-buffered dialysis solutions on peritoneal ultrafiltration: A comparative crossover study. Nephrol Dial Transplant 2009; 24: 1617-1625
77. Davies SJ, Woodrow G, Donovan K et al. Icodextrin improves the fluid status of peritoneal dialysis patients: Results of a double-blind randomized controlled trial. J Am Soc Nephrol 2003; 14: 2338-2344
78. Tranaeus A. A long-term study of a bicarbonate/lactatebased peritoneal dialysis solution-clinical benefits. The Bicarbonate/ Lactate Study Group. Perit Dial Int 2000; 20: 516-523
79. Montenegro J, Saracho RM, Martinez IM et al. Long-term clinical experience with pure bicarbonate peritoneal dialysis solutions. Perit Dial Int 2006; 26: 89-94
80. Weiss L, Stegmayr B, Malmsten G et al. Biocompatibility and tolerability of a purely bicarbonate-buffered peritoneal dialysis solution. Perit Dial Int 2009; 29: 647-655
81. Haag-Weber M, Kramer R, Haake R et al. Low-GDP fluid (Gambrosol trio) attenuates decline of residual renal function in PD patients: A prospective randomized study. Nephrol Dial Transplant 2010; 25: 2288-2296
82. Kim S, Oh KH, Oh J et al. Biocompatible peritoneal dialysis solution preserves residual renal function. Am J Nephrol 2012; 36: 305-316
83. Cho Y, Johnson DW, Craig JC et al. Biocompatible dialysis fluids for peritoneal dialysis. Cochrane Database Syst Rev 2014; 3: CD007554
84. Davies SJ, Garcia Lopez E, Woodrow G et al. Longitudinal relationships between fluid status, inflammation, urine volume and plasma metabolites of icodextrin in patients randomized to glucose or icodextrin for the long exchange. Nephrol Dial Transplant 2008; 23: 2982-2988
85. Konings CJ, Kooman JP, Schonck M et al. Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: A randomized study. Kidney Int 2003; 63: 1556-1563
86. Adachi Y, Nakagawa Y, Nishio A. Icodextrin preserves residual renal function in patients treated with automated peritoneal dialysis. Perit Dial Int 2006; 26: 405-407
87. Posthuma N, ter Wee PM, Verbrugh HA et al. Icodextrin instead of glucose during the daytime dwell in CCPD increases ultrafiltration and 24-h dialysate creatinine clearance. Nephrol Dial Transplant 1997; 12: 550-553
88. Plum J, Gentile S, Verger C et al. Efficacy and safety of a 7.5% icodextrin peritoneal dialysis solution in patients treated with automated peritoneal dialysis. Am J Kidney Dis 2002; 39: 862-871
89. Wolfson M, Piraino B, Hamburger RJ et al. A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis. Am J Kidney Dis 2002; 40: 1055-1065
90. Takatori Y, Akagi S, Sugiyama H et al. Icodextrin increases technique survival rate in peritoneal dialysis patients with diabetic nephropathy by improving body fluid management: A randomized controlled trial. Clin J Am Soc Nephrol 2011; 6: 1337-1344
91. Posthuma N, ter Wee PM, Donker AJ et al. Assessment of the effectiveness, safety, and biocompatibility of icodextrin in automated peritoneal dialysis. The Dextrin in APD in Amsterdam (DIANA) Group. Perit Dial Int 2000; 20(Suppl 2): S106-S113
92. Papakrivopoulou E, Booth J, Pinney J et al. Comparison of volume status in asymptomatic haemodialysis and peritoneal dialysis outpatients. Nephron Extra 2012; 2: 48-54
93. Davenport A,Willicombe M. Comparison of fluid status in patients treated by different modalities of peritoneal dialysis using multi-frequency bioimpedance. Int J Artif Organs 2009; 32: 779-786
94. Inal S, Erten Y, Okyay GU et al. Association between bioimpedance analysis parameters and left ventricular hypertrophy in peritoneal dialysis patients. Int Urol Nephrol 2014; 46: 1851-1856
95. Davenport A, Sayed RH, Fan S. Is extracellular volume expansion of peritoneal dialysis patients associated with greater urine output? Blood Purif 2011; 32: 226-231
96. Fan S, Sayed RH, Davenport A. Extracellular volume expansion in peritoneal dialysis patients. Int J Artif Organs 2012; 35: 338-345
97. Papakrivopoulou E, Lillywhite S, Davenport A. Is N-terminal probrain-type natriuretic peptide a clinically useful biomarker of volume overload in peritoneal dialysis patients? Nephrol Dial Transplant 2012; 27: 396-401
98. McCafferty K, Fan S, Davenport A. Extracellular volume expansion, measured by multifrequency bioimpedance, does not help preserve residual renal function in peritoneal dialysis patients. Kidney Int 2014; 85: 151-157
99. Shemin D, Maaz D, St Pierre D et al. Effect of aminoglycoside use on residual renal function in peritoneal dialysis patients. Am J Kidney Dis 1999; 34: 14-20
100. Baker RJ, Senior H, Clemenger M et al. Empirical aminoglycosides for peritonitis do not affect residual renal function. Am J Kidney Dis 2003; 41: 670-675
101. Badve SV, Hawley CM, McDonald SP et al. Use of aminoglycosides for peritoneal dialysis-associated peritonitis does not affect residual renal function. Nephrol Dial Transplant 2012; 27: 381-387
102. Lui SL, Cheng SW, Ng F et al. Cefazolin plus netilmicin versus cefazolin plus ceftazidime for treating CAPD peritonitis: Effect on residual renal function. Kidney Int 2005; 68: 2375-2380
103. Weisbord SD, Bernardini J, Mor MK et al. The effect of coronary angiography on residual renal function in patients on peritoneal dialysis. Clin Cardiol 2006; 29: 494-497
104. Dittrich E, Puttinger H, Schillinger M et al. Effect of radio contrast media on residual renal function in peritoneal dialysis patients-A prospective study. Nephrol Dial Transplant 2006; 21: 1334-1339
105. Moranne O, Willoteaux S, Pagniez D et al. Effect of iodinated contrast agents on residual renal function in PD patients. Nephrol Dial Transplant 2006; 21: 1040-1045
106. Davies SJ, Davenport A. The role of bioimpedance and biomarkers in helping to aid clinical decision-making of volume assessments in dialysis patients. Kidney Int 2014 Jun 11. doi: 10.1038/ki.2014.207